Which GLP-1 Has Most Weight Loss? Clinical Evidence & Genetics

Last reviewed: May 31, 2026

Last updated: May 31, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Clinical trials show tirzepatide produces greater average weight loss than semaglutide—approximately 21-22% body weight reduction versus 15-17%—but this comparison masks critical individual variation. Real-world outcomes depend on metabolism, genetics, dosing adherence, and lifestyle factors beyond medication efficacy alone.

Selecting the 'most effective' GLP-1 requires moving beyond headline clinical data to understand your metabolic profile and genetic context. PlexusDx supports precision-wellness conversations by revealing how your peptide pathway genetics and biomarkers may influence individual medication response.

Clinical Trial Data: Comparing Average Weight Loss Outcomes

Tirzepatide clinical trials (SUMO series) demonstrated mean weight loss of 21-22% at maximum doses in patients with obesity and type 2 diabetes. Semaglutide trials (STEP series) showed 15-17% average weight loss at highest doses. These averages represent population-level efficacy, not individual predictability.

These trials enrolled carefully selected participants with controlled baseline conditions and high protocol adherence—factors rarely replicated in clinical practice. Real-world outcomes vary widely even among patients on identical medications and doses, suggesting individual biological factors significantly influence response.

Why Individual Weight Loss Response Varies: A Biomarker Framework

Two patients on the same GLP-1 dose may lose 5% versus 25% body weight due to differences in insulin sensitivity, baseline metabolic rate, GLP-1 receptor expression, appetite regulation genetics, and GIPR (glucose-dependent insulinotropic polypeptide receptor) signaling. Population averages obscure this individual heterogeneity.

Biomarker/Factor	Influence on GLP-1 Response
Baseline Insulin Resistance	Higher baseline IR may show greater initial weight loss; metabolic state at treatment start predicts trajectory
GLP-1 Receptor Genetics (rs6923761)	Genetic variants may influence GLP-1R expression and downstream satiety signaling efficiency
GIPR Variants (rs1800437)	GIPR co-activation enhances weight loss; genetic predisposition in GIPR pathway affects tirzepatide vs semaglutide relative benefit
FTO Gene Status (rs9939609)	Risk alleles associated with increased appetite drive; may moderate treatment response independent of medication choice
MC4R Variants (rs17782313)	Involved in melanocortin appetite regulation; genetic context may influence satiety signaling from GLP-1 agonists

Tirzepatide Versus Semaglutide: Beyond the Average Comparison

Tirzepatide activates both GLP-1 and GIPR, while semaglutide targets GLP-1 alone. This dual mechanism typically yields greater weight loss averages, but approximately 30-40% of semaglutide users achieve excellent outcomes, and some tirzepatide responders experience modest results. Mechanism alone does not determine individual efficacy.

Provider selection between these compounds should incorporate baseline metabolic markers (fasting glucose, C-peptide, lipid profile), patient genetics (especially GIPR pathway variants), gastrointestinal tolerance history, and cardiovascular risk profile—not weight-loss averages alone. Dose escalation and protocol adherence equally influence outcomes.

Who Benefits Most: Clinical Context and Candidacy Considerations

Patients with severe insulin resistance, baseline fasting glucose 110+ mg/dL, and family history of type 2 diabetes may see larger weight loss percentages with tirzepatide's dual mechanism. However, those with normal insulin sensitivity or contraindications to GIPR activation may achieve equivalent or superior outcomes with semaglutide.

Before starting any GLP-1 medication, comprehensive metabolic screening (fasting glucose, insulin, lipid panel, HbA1c), assessment of gastrointestinal and cardiovascular risk, and provider conversation about realistic individual expectations are essential. Genetic insights into peptide pathway predispositions can contextualize these discussions but do not predict exact outcomes.

How PlexusDx Supports a More Personalized Approach

PlexusDx Precision Peptide Genetic Test examines key variants in GLP-1R, GIPR, FTO, and MC4R pathways to help provide context about your inherited predispositions in appetite regulation and glucose sensing. These insights may help inform personalized conversations with your provider about which GLP-1 class could align with your metabolic profile.

The genetic test reveals whether you carry risk variants in GIPR signaling (relevant to tirzepatide dual-mechanism benefit), GLP-1 receptor efficiency, and appetite-drive genes. These predispositions do not predict exact weight loss percentages—individual response depends on adherence, diet, exercise, and numerous unmeasured factors—but genetic context supports more informed decision-making.

Understanding your genetic predispositions alongside clinical biomarkers (baseline insulin, metabolic rate, cardiovascular status) enables you and your provider to design a realistic treatment plan tailored to your biology, not population averages. This precision-wellness approach increases the likelihood of sustained success.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $229-$509/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.